Drugs / ND0612
last change Nov 2022 re-read 2 minutes ago

ND0612

Developed for
Parkinson disease
Investigated by
NeuroDerm Ltd. · Quotient Clinical

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02604914 May 2015 → Jun 2016 Parkinson disease NeuroDerm Ltd. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT02726386 May 2016 → Sep 2019 overdue Parkinson disease NeuroDerm Ltd. Active not recruiting No outcome recorded
Phase 2 NCT01883505 Jan 2014 → Apr 2015 Parkinson disease NeuroDerm Ltd. Completed No outcome recorded
Phase 33 trials
Phase 3 NCT04006210 Sep 2019 → Nov 2022 overdue Parkinson disease NeuroDerm Ltd. Active not recruiting No outcome recorded
Phase 3 NCT03462043 Apr → Nov 2018 Parkinson disease NeuroDerm Ltd. Withdrawn No outcome recorded
Phase 3 NCT02782481 Aug 2016 → Oct 2018 Parkinson disease NeuroDerm Ltd. Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as ND0612 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02604914
5

NCT02782481

NCT04006210

NCT02726386

NCT03462043

NCT01883505

Route Subcutaneous Subcutaneous infusion via CRONO ND pump” NCT01883505